RESEARCH NOTE

Saccharomyces cerevisiae show low levels of traversal across the human blood brain barrier *in vitro* [version 1; peer review: 1 approved, 1 approved with reservations]

Roberto Pérez-Torrado , Amparo Querol

Food Biotechnology Department, Institute of Agrochemistry and Food Technology (IATA-CSIC), Paterna, Valencia, Spain

V1 First published: 20 Jun 2017, 6:944
<https://doi.org/10.12688/f1000research.11782.1>
 Latest published: 12 Sep 2017, 6:944
<https://doi.org/10.12688/f1000research.11782.2>

Abstract

Background: *Saccharomyces cerevisiae* is generally considered safe, and is involved in the production of many types of foods and dietary supplements. However, some isolates, which are genetically related to strains used in brewing and baking, have shown virulent traits, being able to produce infections in humans, mainly in immunodeficient patients. This can lead to systemic infections in humans.

Methods: In this work, we studied *S. cerevisiae* isolates in an *in vitro* human blood brain barrier model, comparing their behaviour with that of several strains of the related pathogens *Candida glabrata* and *Candida albicans*.

Results: The results showed that this food related yeast is able to cross the blood brain barrier *in vitro*. However, in contrast to *C. glabrata* and *C. albicans*, *S. cerevisiae* showed very low levels of traversal.

Conclusions: We conclude that using an *in vitro* human blood brain barrier model with *S. cerevisiae* can be useful to evaluate the safety of *S. cerevisiae* strains isolated from foods.

Keywords

food emerging pathogens, *Saccharomyces cerevisiae*, blood brain barrier, virulence

Open Peer Review

Approval Status

	1	2
version 2 (revision) 12 Sep 2017		view

version 1 20 Jun 2017	view	view

1. **Rosa de Llanos**, Edinburgh Napier University, Edinburgh, UK

2. **Felipe H. Santiago-Tirado** , Washington University School of Medicine, St. Louis, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Roberto Pérez-Torrado (rober@iata.csic.es)

Author roles: **Pérez-Torrado R:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Querol A:** Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by grants AGL2012-39937-C02-01 and AGL2015-67504-C3-1-R from the Spanish Government and ERDF (European Regional Development Fund) and by grant PROMETEO (project PROMETEOII/2014/042) from Generalitat Valenciana to AQ.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Pérez-Torrado R and Querol A. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Pérez-Torrado R and Querol A. *Saccharomyces cerevisiae* show low levels of traversal across the human blood brain barrier *in vitro* [version 1; peer review: 1 approved, 1 approved with reservations] F1000Research 2017, 6:944 <https://doi.org/10.12688/f1000research.11782.1>

First published: 20 Jun 2017, 6:944 <https://doi.org/10.12688/f1000research.11782.1>

Introduction

Saccharomyces cerevisiae is generally considered safe, and is involved in the production of a variety of foods and dietary supplements. Several types of food and beverage still contain viable yeast cells^{1–5}. However, in the last years human infections with *Saccharomyces cerevisiae* have increased^{6–8}. Consequently, *S. cerevisiae* is considered an emerging pathogen^{9–11}. Different parts of the body can be affected in immunocompromised^{12–15} and healthy patients^{16–18}. The potential virulence of this yeast has been analysed with different methods *in vitro*^{19–22} and *in vivo*^{23–27}, for example by measuring epithelial barrier traversal²⁸. These reports have suggested that certain strains can cause disease and death in murine models. However, the bio-therapeutic agent Ultralevure (*S. cerevisiae* var. *boulardii*) and other supplements are consumed in high doses, ranging from 10⁷ to 10¹⁰ live yeast cells per day and for long periods.

The study of yeast virulence includes studying their behaviour when they encounter endothelial barriers. Opportunistic pathogenic yeasts such as *C. glabrata* and *C. albicans* are able to pass the intestinal barrier^{29,30} and generate systemic infections^{31–33}. Also, *C. albicans* can cross the blood-brain barrier (BBB) to reach the brain^{34,35}. Regarding *S. cerevisiae*, infections after oral ingestion¹⁶ or digestive translocation^{12,14,36} show that it can reach brain in murine models²⁵. However, few studies have investigated the behaviour of *S. cerevisiae* when they reach endothelial barriers²⁸.

Methods

Yeast strains and growth media

The yeast strains are described in Table 1. Strains were propagated in YPD media (1% glucose, 1% BactoPeptone, 0.5% yeast extract) for 24 h at 30°C.

Growth of mammalian cells

Human umbilical endothelial cells (HUVECs) (Clonetics®) were grown in minimum essential medium (Earle's salt, 25 mM HEPES and GlutaMAX™, Invitrogen) supplemented with 10% foetal bovine serum (FBS, Cambrex Bio Science), 1% nonessential amino acids (Invitrogen) and 50 µg mL⁻¹ gentamicin (Invitrogen). The cells were grown in 150 cm² culture flasks (TPP) at 37°C in a humidified atmosphere of 5% CO₂ and 95% air until a confluence. Culture medium was changed every second day.

Trans-epithelial electrical resistance (TEER) assay

HUVEC cells (1×10⁵ cells cm⁻²) were seeded on Transwell® filter inserts (8 µm, Corning Incorporated) in 24-well plates (Corning Incorporated). A volume of 200 µL cell growth medium was added to the apical compartment and 1250 µL to the basolateral compartment. The TEER was measured using the Millicell-ERS Electrical Resistance System (Millipore). The net value of the TEER (Ωcm⁻²) was corrected for background resistance by subtracting the contribution of the cell-free filter and the medium (110 Ωcm⁻²). The TEER was measured before the addition of yeasts.

Table 1. Yeast strains used in this study.

Strain	Species	Source
W303	<i>S. cerevisiae</i>	From our collection
102	<i>S. cerevisiae</i>	Vall d'Hebron Hospital (Barcelona, Spain) ¹⁹
60	<i>S. cerevisiae</i>	Vall d'Hebron Hospital (Barcelona, Spain) ¹⁹
Cb	<i>S. cerevisiae</i>	Vall d'Hebron Hospital (Barcelona, Spain) ¹⁹
Co	<i>C. glabrata</i>	Vall d'Hebron Hospital (Barcelona, Spain)
C2	<i>C. glabrata</i>	Provided by B. Hube (Friedrich Schiller University; Jena, Germany)
C4	<i>C. glabrata</i>	Provided by B. Hube (Friedrich Schiller University; Jena, Germany)
C5	<i>C. glabrata</i>	Provided by B. Hube (Friedrich Schiller University; Jena, Germany)
CA-1	<i>C. albicans</i>	Statens Serum Institute (Copenhagen, Denmark)
SC5314	<i>C. albicans</i>	Provided by A. Yañez ²² (Universitat de Valencia, Spain)
ATCC26555	<i>C. albicans</i>	Provided by A. Yañez ²² (Universitat de Valencia, Spain)
CBS562	<i>C. albicans</i>	From our collection

Determination of permeability coefficient

1 µg/mL of fluorescein (Sigma) was added to the media in the apical compartment of the transwell, with or without established HUVEC monolayers, and fluorescence was measured over time in the media of the apical and basolateral compartment. The apparent permeability, P_{app} , was defined as (Hilgers *et al.*, 1990):

$$P_{app} = (\Delta A_R / \Delta t) / C_{D,0} \quad (1)$$

($\Delta A_R / \Delta t$) is the rate of drug appearance in the receiver side, S is the surface area of the Transwell (0.33 cm² for Transwell® inserts (8 µm pore size, Corning) of 6.5-mm insert diameter), and $C_{D,0}$ is the initial drug concentration in the donor side at time = 0. Values are expressed in cm/s.

Ability to cross the blood-brain barrier

HUVEC cells were seeded on Transwell® filter as described above. Yeasts grown overnight at 30°C in YPD were resuspended (10⁶ cells mL⁻¹) in the apical compartment and incubated at 37°C in a humidified atmosphere of 5% CO₂ and 95% air. After 12 h, the basolateral compartment medium was replaced. Colony forming units were counted in YPD plate triplicates after two days. Control wells used to evaluate yeast growth showed no significant growth after 12 h.

Results

Evaluation of the blood-brain barrier integrity

To establish an *in vitro* BBB, we used HUVEC monolayers, a methodology that has been widely used^{37,38}. Monolayers were formed in transwells and two different methods were used to determine the robustness, consistency and integrity of the barrier. First, we studied the TEER, indicative of physical separation. After seeding the HUVECs, TEER was measured and we observed increased values over time that were overcoming 450 Ωcm², which correlates with the establishment of a monolayer barrier. Second, we studied the monolayer permeability. The value obtained was 1.82±0.13 (10⁻⁶ cm/s) on average, which indicates an integral barrier with low permeability³⁹.

Study of the ability of yeast species to cross the human BBB *in vitro*

To determine whether *S. cerevisiae* is able to cross the human BBB, we used an *in vitro* model of the human BBB with HUVECs⁴⁰. The number of cells in the basolateral compartment was measured 12 hours after addition of *S. cerevisiae*, *C. albicans* and *C. glabrata* strains to the apical compartment (Figure 1). The results showed that all yeast strains were able to cross the BBB. While elevated number of cells from *C. glabrata* and *C. albicans* strains were able to cross the BBB, *S. cerevisiae* values were low. Furthermore, while the *S. cerevisiae* control strain W303 showed the lowest levels of yeast transcytosis, the other opportunistic pathogenic strains presented higher levels.

To compare the different species, the average level of cell transcytosis for all strains of each species was calculated (Figure 2). After 12 h, *Candida* species showed a high number of cells in the basolateral chamber (4.9–5.7 Log₁₀ units). On the contrary, we observed that *S. cerevisiae* showed significantly lower levels (1.0–3.3 Log₁₀ units) than the *Candida* species.

Figure 1. Number of yeast cells that were able to cross the blood brain barrier. To perform this assay we established HUVEC monolayers in Transwell® filter inserts in 24 well plates. 24 hours after apical addition of various strains of *S. cerevisiae*, *C. albicans* and *C. glabrata*, yeast cells from the basolateral compartment were incubated on YPD plates and colonies were counted after one day of growth. Values were obtained after plating several dilutions of the basolateral compartment media. Average of three experiments and standard deviation is shown. To determine statistically significant data, Student *t*-tests were performed in Excel with 0.05 as the *p*-value.

Figure 2. Box graph comparing the number of cells able to cross the blood brain barrier in the three yeast species.

Dataset 1. Raw data of permeability measurements and cell counts for blood-brain barrier traversal

<http://dx.doi.org/10.5256/f1000research.11782.d165113>

Discussion

A model for traversal across the BBB *in vitro* has been used to study behaviour and pathogenicity mechanisms of yeast strains such as *C. albicans*^{34,35}. Here, we have shown that *S. cerevisiae* strains are able to cross the BBB. This data is in accordance with

previous studies, where *S. cerevisiae* cells were observed in the brain after systemic infections in murine models²⁵. When comparing to other well-known yeast pathogens such as *C. glabrata* and *C. albicans*, none of the *S. cerevisiae* strains were able to cross the BBB at high levels. Despite *S. cerevisiae* pathogenicity levels being lower than other opportunistic yeasts, we recommend the potential risk of new *S. cerevisiae* strains to be evaluated before using them in food production.

Data availability

Dataset 1: Raw data of permeability measurements and cell counts for BBB traversal. DOI, [10.5256/f1000research.11782.d165113](https://doi.org/10.5256/f1000research.11782.d165113)⁴¹

Competing interests

No competing interests were disclosed.

Grant information

This work was supported by grants AGL2012-39937-C02-01 and AGL2015-67504-C3-1-R from the Spanish Government and ERDF (European Regional Development Fund) and by grant PROMETEO (project PROMETEOII/2014/042) from Generalitat Valenciana to AQ.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Fröhlich-Wyder MT: **8 – Yeasts in dairy products.** In: *Yeasts in Food. Beneficial and Detrimental Aspects*. Boekhout T, Robert V, Editors. Behr, Hamburg. 2003; 209–237.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jacques N, Casaregola S: **Safety assessment of dairy microorganisms: the hemiascomycetous yeasts.** *Int J Food Microbiol.* 2008; **126**(3): 321–326.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Deak T, Beuchat L: **Handbook of spoilage yeasts.** CRC, Boca Raton; 1996.
[Reference Source](#)
- Loureiro V, Malfaito-Ferreira M: **Spoilage yeasts in the wine industry.** *Int J Food Microbiol.* 2003; **86**(1–2): 23–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Loureiro V, Querol A: **The prevalence and control of spoilage yeasts in foods and beverages.** *Trends Food Sci Technol.* 1999; **10**(11): 356–365.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Herbrecht R, Nivoix Y: **Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration.** *Clin Infect Dis.* 2005; **40**(11): 1635–1637.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Montineri A, Lacobello C, Larocca L, et al.: **[Saccharomyces cerevisiae fungemia associated with multifocal pneumonia in a patient with alcohol-related hepatic cirrhosis].** *Infez Med.* 2008; **16**(4): 227–229.
[PubMed Abstract](#)
- Swinne D, Nolard N, VAN Rooij P, et al.: **Bloodstream yeast infections: a 15-month survey.** *Epidemiol Infect.* 2009; **137**(7): 1037–1040.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hazen KC: **New and emerging yeast pathogens.** *Clin Microbiol Rev.* 1995; **8**(4): 462–478.
[PubMed Abstract](#) | [Free Full Text](#)
- Murphy A, Kavanagh K: **Emergence of Saccharomyces cerevisiae as a human pathogen. Implications for biotechnology Review.** *Enzyme Microb Technol.* 1999; **25**(7): 551–557.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pontón J, Rüchel R, Clemons KV, et al.: **Emerging pathogens.** *Med Mycol.* 2000; **38**(Suppl 1): 225–36.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Enache-Angoulvant A, Hennequin C: **Invasive Saccharomyces infection: a comprehensive review.** *Clin Infect Dis.* 2005; **41**(11): 1559–1568.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lolis N, Veldekis D, Moraitou H, et al.: **Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.** *Crit Care.* 2008; **12**(2): 414.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Muñoz P, Bouza E, Cuenca-Estrella M, et al.: **Saccharomyces cerevisiae fungemia: an emerging infectious disease.** *Clin Infect Dis.* 2005; **40**(11): 1625–1634.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Williams JS, Mufti GJ, Powell S, et al.: **Saccharomyces cerevisiae emboli in an immunocompromised patient with relapsed acute myeloid leukaemia.** *Clin Exp Dermatol.* 2007; **32**(4): 395–397.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jensen DP, Smith DL: **Fever of unknown origin secondary to brewer's yeast ingestion.** *Arch Intern Med.* 1976; **136**(3): 332–333.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Smith D, Metzgar D, Wills C, et al.: **Fatal Saccharomyces cerevisiae aortic graft infection.** *J Clin Microbiol.* 2002; **40**(7): 2691–2692.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sobel JD, Schmitt CA, Lynch M, et al.: **Emerging problem of vaginitis due to Saccharomyces cerevisiae.** *Clin Infect Dis.* 1993; **16**: 93–94.
- de Llanos R, Fernández-Espinar MT, Querol A: **A comparison of clinical and food Saccharomyces cerevisiae isolates on the basis of potential virulence factors.** *Antonie van Leeuwenhoek.* 2006; **90**(3): 221–231.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Klingberg TD, Lesnik U, Arneborg N, et al.: **Comparison of Saccharomyces cerevisiae strains of clinical and nonclinical origin by molecular typing and determination of putative virulence traits.** *FEMS Yeast Res.* 2008; **8**(4): 631–640.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- McCusker JH, Clemons KV, Stevens DA, et al.: **Saccharomyces cerevisiae virulence phenotype as determined with CD-1 mice is associated with the ability to grow at 42 degrees C and form pseudohyphae.** *Infect Immun.* 1994; **62**(12): 5447–5455.
[PubMed Abstract](#) | [Free Full Text](#)
- Yáñez A, Murciano C, Llopis S, et al.: **In vivo and in vitro studies on virulence and host responses to Saccharomyces cerevisiae clinical and non-clinical isolates.** *Open Mycol J.* 2009; **3**: 37–47.
[Publisher Full Text](#)
- Byron JK, Clemons KV, McCusker JH, et al.: **Pathogenicity of Saccharomyces cerevisiae in complement factor five-deficient mice.** *Infect Immun.* 1995; **63**(2): 478–485.
[PubMed Abstract](#) | [Free Full Text](#)
- Clemons KV, McCusker JH, Davis RW, et al.: **Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae.** *J Infect Dis.* 1994; **169**(4): 859–867.
[PubMed Abstract](#) | [Publisher Full Text](#)
- de Llanos R, Llopis S, Molero G, et al.: **In vivo virulence of commercial Saccharomyces cerevisiae strains with pathogenicity-associated phenotypical traits.** *Int J Food Microbiol.* 2011; **144**(3): 393–399.
[PubMed Abstract](#) | [Publisher Full Text](#)
- McCullough MJ, Clemons KV, McCusker JH, et al.: **Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.).** *J Clin Microbiol.* 1998; **36**(9): 2613–2617.
[PubMed Abstract](#) | [Free Full Text](#)
- Llopis S, Querol A, Heyken A, et al.: **Transcriptomics in human blood incubation reveals the importance of oxidative stress response in Saccharomyces cerevisiae clinical strains.** *BMC Genomics.* 2012; **13**: 419.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Pérez-Torrado R, Llopis S, Jespersen L, et al.: **Clinical Saccharomyces cerevisiae isolates cannot cross the epithelial barrier in vitro.** *Int J Food Microbiol.* 2012; **157**(1): 59–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Li L, Redding S, Dongari-Bagtzoglou A: **Candida glabrata: an emerging oral opportunistic pathogen.** *J Dent Res.* 2007; **86**(3): 204–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Naglik JR, Moyes DL, Wächter B, et al.: **Candida albicans interactions with epithelial cells and mucosal immunity.** *Microbes Infect.* 2011; **13**(12–13): 963–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

31. Brun S, Dalle F, Saulnier P, *et al.*: **Biological consequences of petite mutations in *Candida glabrata***. *J Antimicrob Chemother.* 2005; **56**(2): 307–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Dalle F, Wächtler B, L'Ollivier C, *et al.*: **Cellular interactions of *Candida albicans* with human oral epithelial cells and enterocytes**. *Cell Microbiol.* 2010; **12**(2): 248–271.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Hoarau G, Kerdraon O, Lagree M, *et al.*: **Detection of (1,3)- β -D-glucans *in situ* in a *Candida albicans* brain granuloma**. *J Infect.* 2013; **67**(6): 622–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Jong AY, Stins MF, Huang SH, *et al.*: **Traversal of *Candida albicans* across human blood-brain barrier *in vitro***. *Infect Immun.* 2001; **69**(7): 4536–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Jong AY, Chen SH, Stins MF, *et al.*: **Binding of *Candida albicans* enolase to plasmin(ogen) results in enhanced invasion of human brain microvascular endothelial cells**. *J Med Microbiol.* 2003; **52**(Pt 8): 615–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Lherm T, Monet C, Nougère B, *et al.*: **Seven cases of fungemia with *Saccharomyces boulardii* in critically ill patients**. *Intensive Care Med.* 2002; **28**(6): 797–801.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Langford D, Hurlford R, Hashimoto M, *et al.*: **Signalling crosstalk in FGF2-mediated protection of endothelial cells from HIV-gp120**. *BMC Neurosci.* 2005; **6**: 8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Wilhelm I, Fazakas C, Krizbai IA: ***In vitro* models of the blood-brain barrier**. *Acta Neurobiol Exp (Wars).* 2011; **71**(1): 113–128.
[PubMed Abstract](#)
39. Gaillard PJ, de Boer AG: **Relationship between permeability status of the blood-brain barrier and *in vitro* permeability coefficient of a drug**. *Eur J Pharm Sci.* 2000; **12**(2): 95–102.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Sun SW, Zu XY, Tuo QH, *et al.*: **Caveolae and caveolin-1 mediate endocytosis and transcytosis of oxidized low density lipoprotein in endothelial cells**. *Acta Pharmacol Sin.* 2010; **31**(10): 1336–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Pérez-Torrado R, Querol A: **Dataset 1 in: Low levels of *in vitro* human blood brain barrier traversal of the food related emerging pathogen *Saccharomyces cerevisiae***. *F1000Research.* 2017.
[Data Source](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 01 September 2017

<https://doi.org/10.5256/f1000research.12728.r25622>

© 2017 Santiago-Tirado F. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Felipe H. Santiago-Tirado

Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA

Although the article is interesting and the data clear, I believe the authors are overstating the findings. First, HUVECs are not considered a good model for blood-brain barrier anymore. They used to be a favorite one because they are a human cell line, however, they are not of cerebral origin, and deviate considerably from the behavior of cerebral endothelial cells. They could fix this by calling their model an "endothelial" monolayer instead, or repeat the experiment using "real" BBB cell lines (i.e. hCMEC/D3, which is commercially available). Also, they report the TEER values (which by the way the correct units should be resistance (ohms) times area (cm²) rather than dividing by it) before the start of the experiment, but they should also measure the integrity of the monolayer at the end of the experiment, to rule out that the amount of *S. cerevisiae* crossing is due to rupture of the monolayer. This assay is also hard to interpret in the absence of a negative control - in fact, *S. cerevisiae* has been traditionally used as a negative control on this type of assays! Would inert beads also cross? Would any other organisms cross at the same rate? Maybe they can check this by using fluorescent beads and measuring fluorescence on the bottom. Or if easier to do by CFUs, they could add another organism known to not been able to cross and count CFUs. Overall, it is a nice preliminary report, one worth the time pursuing. Considering this was submitted as a Research Note, I believe is appropriate for indexing once they address my comments above.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Fungal pathogenesis

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 14 August 2017

<https://doi.org/10.5256/f1000research.12728.r24594>

© 2017 de Llanos R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rosa de Llanos

School of Applied Sciences, Edinburgh Napier University, Edinburgh, UK

1. Introduction:

I would consider to change the sentence "Consequently, *S. cerevisiae* is considered an emerging pathogen" with "Consequently, *S. cerevisiae* is considered an emerging pathogen **of low virulence**"

2. Origin of isolation of the yeast strains could be included in Table 1.

3. Methods:

Abbreviation of BBB should be added in the title Ability to cross the blood-brain barrier.

4. Results:

In Figure 1 there are different colours but not information about the meaning of it has been included. In Figure 2, there is a mistake for *C. glabrata* and *C. albicans*, they are named as *S. glabrata* and *S. albicans*.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Fungal pathogenesis, food microbiology, environmental microbiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research